Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Breast Neoplasms 2Genetic Diseases, Inborn 1

Interventions

Letrozole 34Fulvestrant 31Specimen Handling 29ribociclib 22pembrolizumab 22Paclitaxel 21Magnetic Resonance Spectroscopy 20palbociclib 19Trastuzumab 19Anastrozole 19Carboplatin 18Capecitabine 18exemestane 17abemaciclib 16Biopsy 16Tamoxifen 15pertuzumab 14trastuzumab deruxtecan 12Cyclophosphamide 10Taxes 9Radiotherapy 8Goserelin 8Docetaxel 8giredestrant 7Standard of Care 7130-nm albumin-bound paclitaxel 7inavolisib 6eribulin 6elacestrant 6atezolizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Alpelisib × Breast × 30 days × Clear all
NCT05038735 2026-06-02

EPIK-B5

Novartis

Phase 3 Active not recruiting
210 enrolled
Breast

Breast Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡